What is Neffy?
Neffy is an FDA-approved nasal spray version of epinephrine, used to treat severe allergic reactions like anaphylaxis. Unlike traditional auto-injectors such as EpiPen, it delivers a 2 mg dose through the nose, making it needle-free and easier for some users to carry and administer.[1]
How does Neffy work?
It uses intranasal delivery to rapidly absorb epinephrine into the bloodstream, reversing symptoms of anaphylaxis such as airway swelling, low blood pressure, and hives. The spray is single-use, with one puff into one nostril; a second dose can follow if needed after 5 minutes.[1][2]
Who makes Neffy and when was it approved?
ARCTURUS Therapeutics and ALK developed Neffy. The FDA approved it in August 2024 for adults and children weighing at least 30 kg (66 lbs), with a lower 1 mg dose approved later for kids 15 kg and up.[1][3]
How does Neffy compare to EpiPen?
Neffy avoids needles, weighs less (under 1 oz vs. EpiPen's 0.3 lb), and doesn't require thigh injection, addressing common barriers like needle phobia or fumbling under stress. Both provide quick epinephrine relief, but Neffy may have slightly slower absorption in some studies. EpiPen dominates the market with established use.[1][4]
When does Neffy's patent expire?
Core patents for Neffy's formulation and delivery, held by ARCTURUS, extend protection into the 2030s. Check DrugPatentWatch.com for exact expiry dates, litigation status, and generic entry risks.[5]
What are common Neffy side effects?
Most users report mild effects like nasal irritation, headache, or throat tightness. Serious risks mirror epinephrine: rapid heartbeat, tremors, or high blood pressure. It's contraindicated in narrow-angle glaucoma or certain heart conditions.[1][2]
Neffy pricing and availability
A two-pack costs around $725 without insurance, though patient assistance programs offer it free or low-cost for eligible users. It's available by prescription at pharmacies nationwide since late 2024.[3][6]
Who should use Neffy over injectors?
Ideal for those with needle fears, young kids, or active lifestyles. Not suitable for infants under 15 kg or severe nasal congestion. Doctors weigh it against proven injectors based on patient needs.[4]
[1]: FDA.gov - Neffy Approval Announcement (https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray)
[2]: Neffy.com - Prescribing Information (https://neffy.com/)
[3]: ALK press release (https://www.alk.net/news/alk-receives-fda-approval-for-neffy-epinephrine-nasal-spray-for-the-treatment-of-type-i-severe-allergic-reactions-including-anaphylaxis-in-patients-15-kg-33-lbs-and-older/)
[4]: Journal of Allergy and Clinical Immunology (comparison studies)
[5]: DrugPatentWatch.com - Neffy Patents (https://www.drugpatentwatch.com/p/tradename/NEFFY)
[6]: GoodRx - Neffy Pricing (https://www.goodrx.com/neffy)